[Changes and clinical significance of serum soluble Apo-1/Fas in pancreatic cancer].
OBJECTIVE
To detect changes of serum soluble Apo-1/Fas (sApo-1/Fas) in pancreatic cancer patients and to investigate its clinical value in assessing the effect of chemotherapy.


METHODS
The serum level of sApo-1/Fas in 30 normal control subjects and 58 pancreatic cancer patients were detected using enzyme-linked immunosorbent assay (ELISA), and the sApo-1/Fas level of 48 pancreatic cancer patients, before and after chemotherapy was compared.


RESULTS
Compared with the level of the control group, the level of serum soluble Apo-1/Fas was significantly correlated with clinical stage but not with age, sex or pathologic type of pancreatic cancer. It was elevated gradually from stage II to IV (P < 0.01). However, it would obviously decrease in pancreatic cancer patients after chemotherapy (P < 0.01).


CONCLUSIONS
The serum soluble Apo-1/Fas may be involved in the development of pancreatic cancer, and it may be used as one parameter to assess the disease status and prognosis of pancreatic cancer patient.
Liang
Qi-lian
QL
Department of Medical Oncology, Hospital of Guangdong Medical College, Zhanjiang 524001, China. lianqilian@gdmc.edu.cn
Pan
Da-chao
DC
Yin
Zheng-min
ZM
Liu
Guo-xun
GX
Yang
Qin
Q
Xie
Jie-rong
JR
Fu
You-wen
YW
Cai
Liang-zhen
LZ
D002288:Adenocarcinoma, Mucinous / Q000097:blood / Q000188:drug therapy; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D021441:Carcinoma, Pancreatic Ductal / Q000097:blood / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000188:drug therapy; D011379:Prognosis; D012074:Remission Induction; D019014:fas Receptor / Q000097:blood*; D000093542:Gemcitabine
D019014:fas Receptor; D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine